Home » Newsletters » BioWorld Science

BioWorld Science

March 28, 2008

View Archived Issues

Recent Allergan patent divulges novel antiglaucoma agents

Novel agents for treating allergic disorders disclosed in recent Array patent

Recent patents describe novel antidepressant and antipsychotic agents

ARRY-520 shows less chemoresistance-inducing potential than paclitaxel in vitro

Novel erbB2 inhibitor shows efficacy in different preclinical cancer models

Preclinical profile of Wyeth's novel progesterone receptor modulator

Novel GnRH allosteric modulator discovered at Organon

Vermillion announces positive results from clinical trial of ovarian tumor triage test

Oncolin changes name from Edgeline Holdings and provides update on activities

Ardea presents update on its 2008 plans

Sonus refines strategic initiatives and focuses on development of SN-2310 in cancer

Targeted Genetics reports interim data from phase I/II clinical trial of tgAAC-94

Genentech initiates clinical development in the U.S. and U.K. of cancer drug GDC-0941

Adherex initiates phase III trial of sodium thiosulfate for hearing loss in children

Nventa reports positive interim data from HspE7 phase I cervical dysplasia trial

AEterna Zentaris initiates second phase III trial of cetrorelix for benign prostatic hyperplasia

ExonHit announces results from phase I study of EHT-0202 for brain impairments

Lorus initiates toxicology studies of anticancer drug LOR-253

Oxigene initiates dosing in phase II study of Zybrestat for NSCLC

Roswell Park Cancer Institute awarded USD 900,000 grant for ovarian cancer vaccine

Trubion provides update on product pipeline

European Commission approves novel oral anticoagulant Pradaxa

Positive results for VX-770, Vertex's cystic fibrosis protein modulator

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...